WHO WE ARE

SPECIALIST CONSULTANCY TEAM

Dr Patrick Trotter

Director of Specialist Consultancy

Dr Rashmi Raju

Regulatory & Market Access Manager

Stefanie Read

Principal Specialist, Regulatory & Commercialisation

WHO WE ARE

WHY WORK WITH MEDILINK SPECIALIST CONSULTANCY?

Sector Expertise

Our team brings extensive experience across MedTech, diagnostics, digital health and life sciences. Combining regulatory, clinical, innovation and commercialisation expertise, we provide practical guidance tailored to the specific challenges of highly regulated healthcare markets.

End-to-End Support

From early-stage innovation and evidence generation through to regulatory approval, market access and commercialisation, we provide connected support throughout the product lifecycle. Our multidisciplinary approach ensures technical, regulatory and commercial considerations are aligned from the outset.

Trusted Industry Partner

As part of Medilink’s established healthcare and life sciences network, we work closely with innovators, manufacturers, NHS organisations, universities and investors. Our independent, objective advice helps organisations make informed decisions with confidence.

WHAT THEY SAY

SPECIALIST CONSULTANCY TESTIMONIALS

Tony Bairstow

A recent international strategy report by Rashmi at Medilink has been invaluable in outlining market opportunities across the UK, Europe, and the US. As with many medical products, Aritex Biotech’s proposition spans multiple geographies but faces distinct regulatory and market challenges within each. A concise description of these challenges, along with a strategy to address them, fits well within our business plan and demonstrates both a commitment to entering these markets combined with careful preparation from the outset.

Graham Oliver

The support we received from Rashmi at Medilink was extremely valuable. The export report provided clear insights into potential international markets and practical steps to help us begin exporting with confidence. It was well-structured, easy to understand and tailored to our business needs. This support has given us greater clarity and a stronger foundation for our future international growth.

Adam Levick

Rashmi and the team at Medilink have been an enormous support to Surgical Innovations as we continue to expand our   international operation. The consultation work provided, allowed us to optimise our market understanding and preparation activities for the South America and Southeast Asia region, through the detailed context provided. Medilink also support us, via their membership programme, at an array of international congresses with a meticulous and exemplary service pre, during and post each event, allowing Surgical Innovations to focus on maximising our return from the investment made.

Mark Taylor

The Medilink Innovation and Commercialisation and Regulatory course was fantastic with relevant content bespoke to our request for training. The interactive content and innovation management tools will help us manage and optimise our portfolio. The learnings gained from this course have upskilled our entire team. Great course!

Graham Milward

Medilink provided us with consultancy services which covered extending the intended purpose and product claims for one of our legacy devices. The work identified key user needs associated with using the device for a new clinical indication and has helped us articulate a series of new claims and has fed into our R&D projects in designing new predictive test methods, identifying the acceptability of the benefit risk ratio from competitor benchmarking and also input into our clinical evidence general plans. We look forward to working with Medilink in the future.

Wayne Austin

Medilink have authored a number of clinical evaluation reports for our family of class III implantable tissue regenerative products and we have been delighted in the speed and quality of the service and reports, which have also satisfied the notified body. We look forward to continuing our relationship with Medilink

Harsha Siani

Medilink has been instrumental in helping us navigate complex UK, EU, and US regulations, develop a compelling value proposition, and refine our product labelling and positioning strategy. The Medilink team also provided crucial guidance on planning and understanding the structure, as well as the primary and secondary endpoints, of future clinical trials—insights that will be invaluable for our resource allocation and strategic planning. Furthermore, they identified potential partners through thorough due diligence, assessing gaps in their portfolios and their preferred strategic approaches to growth. Medilink’s contribution has been invaluable in advancing our journey toward commercialization.

Dr Stewart Lowth CEng MIMechE

The contribution of the Medilink team has helped to establish the resources, costs and timelines for commercialisation, which has been invaluable in our R&D planning. Metlase look forward to working with the Medilink team in the future as the project progresses.”